Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

August 11, 2023
Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-termMizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

Jared Holz, Mizuho healthcare strategist, joins ‘Squawk Box’ to discuss Novo Nordisk’s quarterly earnings results, which hiked its outlook for 2023 after reporting a 30% increase in sales for the first half of the year, powered by strong demand for its weight loss drugs, and more.

Share This

Latest Mizuho News

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

April 20, 2026
Iran war highlights risks in the chemical supply chain

Iran war highlights risks in the chemical supply chain

April 15, 2026
Wall Street jumps to near one-month highs after US-Iran ceasefire

Wall Street jumps to near one-month highs after US-Iran ceasefire

April 8, 2026

Mizuho news from around the globe

back-to-top-blue